14 ফলাফল
BACKGROUND OF THE INVENTION
The present invention relates generally to the field of medicine, particularly to the treatment of cancer, and more particularly, to new and useful methods for treating certain types of cancer sensitive to particular glycoside compounds.
Although molecular biology has
STATEMENT ACCORDING TO 37 C.F.R. .sctn.1.821(c) or (e)-SEQUENCE LISTING SUBMITTED AS TXT AND PDF FILES
Pursuant to 37 C.F.R. .sctn.1.821(c) or (e), a file containing a TXT version and a PDF version of the Sequence Listing have been submitted concomitant with this application, the contents of which
BACKGROUND
Cancer treatment regimens are frequently challenged by multi-drug resistance as tumor cells adapt in response to drug treatment. Apoptosis, a type of programmed cell death, involves a series of biochemical events that lead to changes in cell morphology and death. The apoptotic process is
TECHNICAL FIELD
The present invention relates, in general, to a method for gastric cancer diagnosis through the detection of glycan changes, a kit for gastric cancer diagnosis, and a method for detecting glycan changes in order to provide gastric cancer diagnosis information. More particularly, the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to bifunctional glycoproteins having targeting protein and enzyme properties. More particularly, the invention relates to such proteins whose complements of carbohydrate residues have been modified in a manner that enhances
FIELD OF THE INVENTION
The present invention relates to pharmaceuticals that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis both in vitro and in vivo.
Background of the Invention
Cell adhesion is one important property that differentiates multi-cellular organisms from
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn.371 of International Application No. PCT/IN2013/000806 filed 27 Dec. 2013, which claims priority to Indian Patent Application No. 0017/DEL/2013 filed 3 Jan. 2013. The entire contents of
RELATED APPLICATIONS
This application is the National Phase of International Application No. PCT/EP2016/068813, filed Aug. 5, 2016 which designated the U.S. and that International Application was published under PCT Article 21(2) in English, and claims priority to European Application Serial No.
The present invention relates to the use of modified oligo-.beta.-(1,3)-glucans of formula (I) or (II) below for the preparation of medicaments which are useful in treatments based on the stimulation of the immune system.
The glucans, which are natural products, have long been studied and the
This application is based on and claims priority from Provisional Application Ser. No. 60/006,844, filed Nov. 16, 1995.
TECHNICAL FIELD
The present invention relates, in general, to a tumor suppressor and, in particular, to the mannose 6-phosphate/insulin-like growth factor-II (M6P/IGF-II) receptor
The invention relates to novel antibodies directed against the oligosaccharide portion of glycoproteins, methods of preparing said antibodies and oligosaccharide-haptens and clones for generating these antibodies. The novel antibodies are suited for tumor diagnosis and therapy as they are capable of
This invention relates to a monoclonal antibody and a method for the production thereof. More particularly, it relates to a monoclonal antibody specific for a .alpha..sub.1 -acid glycoprotein or specific for at least one antigenic determinant included in a sugar chain of the following formula which
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Phase Application of PCT/HR2014/000022, filed Jun. 11, 2014, which claims priority to Croatian Patent Application No. P20130568A, filed Jun. 20, 2013, the contents of such applications being incorporated by reference
TECHNICAL FIELD
The invention relates to compounds useful in the treatment of inflammation, allergic reactions, autoimmune diseases, cancer, and similar other conditions that are cell adhesion-dependent. More specifically, the invention concerns compounds, containing GalNAc lewis.sup.x as a mucin